EUCTR2010-020375-24-IT进行中（未招募）不适用
Sorafenib in recurrent and/or metastatic salivary gland carcinomas - ND
ISTITUTO NAZIONALE PER LA CURA TUMORI0 个研究点开始时间: 2010年7月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically proven relapsed and/or metastatic salivary gland cancer for which potentially curative options such as surgery or radiotherapy are not indicated. 2. Subjects with at least one uni-dimensional measurable lesion by CT-scan or MRI according to RECIST criteria (target lesion). A previously treated lesion by radiotherapy can be chosen as target lesion only if progression in the respective lesion has been demonstrated during or following radiotherapy.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Symptomatic metastatic brain or meningeal tumors unless the patient is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry 2. History of cardiac disease: congestive heart failure >NYHA class 2; active CAD (MI more than 6 mo prior to study entry is allowed); cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted) or uncontrolled hypertension
研究者
相似试验
已完成
2 期
Activity of Sorafenib in Salivary Gland CancerSalivary Gland CancerNCT01703455Fondazione IRCCS Istituto Nazionale dei Tumori, Milano37
进行中（未招募）
不适用
Sorafenib in the first line treatment of advanced hepatocellular carcinoma with ChildPugh liver function class B. Multicentre phase 3 randomized trial - BOOSTadvanced hepatocellular carcinoma with ChildPugh liver function class BMedDRA version: 9.1Level: LLTClassification code 10024720EUCTR2009-013870-42-ITISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
已完成
2 期
First line Therapy by Sorafenib for Lung Metastases Patients in Renal Cell CarcinomaRenal cell carcinomaJPRN-UMIN000005090Kobe University Graduate school of Medicine100
已完成
2 期
Intermittent treatment with sorafenib in combination with transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): a randomized open-label phase 2 studyC22.0Liver cell carcinomaDRKS00012551Dekanat des Fachbereichs Medizin Klinikum der Johann Wolfgang Goethe-Universität, Haus 154
进行中（未招募）
1 期
Phase II study of sorafenib in malignant mesothelioma previously treated with platinum-based chemotherapy - SMSMalignant MesotheliomaMedDRA version: 13.1Level: PTClassification code 10027407Term: Mesothelioma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-005091-13-GBGuy's & St Thomas' NHS Foundation Trust55